Octagon Capital Advisors’s Faeth Therapeutics FTH Stock Holding History

Octagon Capital Advisors’s Portfolio FTH Stock Details FTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.03M	Buy	+361,010	New	+$8.35M	0.81%	22

Other funds holding FTH

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Balyasny Asset Management

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

Octagon Capital Advisors's FTH Position: Q2 2026 in Review

Octagon Capital Advisors opened a new position in Faeth Therapeutics (FTH) in Q2 2026: 361,010 shares worth $9.03M. The stake represents 0.81% of the portfolio and ranks #22 among its holdings.

45 funds tracked by Wall St. Rank hold FTH as of Q2 2026.

Octagon Capital Advisors held 361,010 shares of Faeth Therapeutics worth $9.03M as of Q2 2026.
Faeth Therapeutics was a new Octagon Capital Advisors position in Q2 2026.
Faeth Therapeutics made up 0.81% of Octagon Capital Advisors's portfolio in Q2 2026, its #22 holding.
45 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2026.

Based on Octagon Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.